The aging process known as senescence is a mechanism involved in the failure of CAR T-cell therapy, according to a study by researchers at the Mayo Clinic.
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a cytokine-armored CAR T-cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.
